IL248258B - Analogues of 4h-pyrazolo[5,1-a]benzimidazole compounds as PARP inhibitors - Google Patents

Analogues of 4h-pyrazolo[5,1-a]benzimidazole compounds as PARP inhibitors

Info

Publication number
IL248258B
IL248258B IL248258A IL24825816A IL248258B IL 248258 B IL248258 B IL 248258B IL 248258 A IL248258 A IL 248258A IL 24825816 A IL24825816 A IL 24825816A IL 248258 B IL248258 B IL 248258B
Authority
IL
Israel
Prior art keywords
pyrazolo
analogs
parp inhibitors
benzimidazole compounds
benzimidazole
Prior art date
Application number
IL248258A
Other languages
English (en)
Hebrew (he)
Original Assignee
Hubei Bio Pharmaceutical Industrial Tech Institute Inc
Humanwell Healthcare Group Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410144173.0A external-priority patent/CN104974161B/zh
Application filed by Hubei Bio Pharmaceutical Industrial Tech Institute Inc, Humanwell Healthcare Group Co Ltd, Medshine Discovery Inc filed Critical Hubei Bio Pharmaceutical Industrial Tech Institute Inc
Publication of IL248258B publication Critical patent/IL248258B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL248258A 2014-04-10 2016-10-09 Analogues of 4h-pyrazolo[5,1-a]benzimidazole compounds as PARP inhibitors IL248258B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410144173.0A CN104974161B (zh) 2014-04-10 2014-04-10 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
CN201510113090 2015-03-13
PCT/CN2015/075363 WO2015154630A1 (zh) 2014-04-10 2015-03-30 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物

Publications (1)

Publication Number Publication Date
IL248258B true IL248258B (en) 2018-11-29

Family

ID=54287319

Family Applications (1)

Application Number Title Priority Date Filing Date
IL248258A IL248258B (en) 2014-04-10 2016-10-09 Analogues of 4h-pyrazolo[5,1-a]benzimidazole compounds as PARP inhibitors

Country Status (22)

Country Link
US (1) US9856262B2 (en:Method)
EP (1) EP3130592B1 (en:Method)
JP (1) JP6359175B2 (en:Method)
KR (1) KR101921486B1 (en:Method)
CN (1) CN106459057B (en:Method)
AU (1) AU2015245786B2 (en:Method)
BR (1) BR112016023397B1 (en:Method)
CA (1) CA2944801C (en:Method)
DK (1) DK3130592T3 (en:Method)
ES (1) ES2754590T3 (en:Method)
HU (1) HUE047410T2 (en:Method)
IL (1) IL248258B (en:Method)
MX (1) MX368496B (en:Method)
NZ (1) NZ725165A (en:Method)
PL (1) PL3130592T3 (en:Method)
PT (1) PT3130592T (en:Method)
RU (1) RU2672722C2 (en:Method)
SA (1) SA516380051B1 (en:Method)
SG (1) SG11201608438YA (en:Method)
TW (1) TWI671301B (en:Method)
WO (1) WO2015154630A1 (en:Method)
ZA (1) ZA201607736B (en:Method)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974161B (zh) * 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
WO2017054755A1 (zh) * 2015-09-30 2017-04-06 湖北生物医药产业技术研究院有限公司 4H-吡唑并[1, 5-α]苯并咪唑类化合物的盐型、晶型及其制备方法和中间体
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
CN110536892B (zh) 2017-04-27 2023-05-12 拜耳动物保健有限责任公司 新的二环吡唑衍生物
CN115028641B (zh) * 2022-07-19 2024-05-28 湖南大学 一种钴催化合成5,8-双官能团取代咪唑并[1,2-a]吡嗪类化合物的方法
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025056690A1 (en) 2023-09-12 2025-03-20 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Parp1- and immune-checkpoint inhibitors for the treatment of cancer patients overexpressing ubqln1 and/or ubqln4
CN116969954B (zh) * 2023-09-21 2023-11-28 广东省农业科学院农业质量标准与监测技术研究所 一类含内酰胺的三环稠合杂环化合物及其应用
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
CN117534677B (zh) * 2024-01-09 2024-03-12 广东省农业科学院农业质量标准与监测技术研究所 一类含亚胺的三环稠合杂环化合物及其应用
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916051A (en) * 1987-04-07 1990-04-10 Konica Corporation Silver halide color photographic light-sensitive material
JP4926720B2 (ja) * 2003-12-22 2012-05-09 スミスクライン ビーチャム （コーク） リミテッド Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
WO2007076127A2 (en) 2005-12-22 2007-07-05 Biogen Idec Ma Inc Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
WO2007144669A1 (en) * 2006-06-15 2007-12-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp)
ES2559679T3 (es) * 2006-06-20 2016-02-15 Abbvie Inc. Pirazoloquinazolinonas como inhibidores de PARP
GB0701273D0 (en) 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
PL2656843T3 (pl) 2012-04-26 2015-08-31 Synbias Pharma Ag Estry bendamustyny i związki pokrewne i ich medyczne zastosowanie
EA027628B1 (ru) 2012-05-04 2017-08-31 Мерк Патент Гмбх Производные пирролотриазинона
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
JP2015522557A (ja) 2012-06-07 2015-08-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト タンキラーゼのピロロピリミドン及びピロロピリドン阻害剤
AU2013288265B2 (en) 2012-07-09 2017-04-06 Lupin Limited Tetrahydroquinazolinone derivatives as PARP inhibitors
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
CN104507912B (zh) * 2012-08-08 2016-09-28 默克专利股份公司 (氮杂-)异喹啉酮衍生物
CN104974161B (zh) 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物

Also Published As

Publication number Publication date
NZ725165A (en) 2018-04-27
BR112016023397B1 (pt) 2022-08-16
SA516380051B1 (ar) 2020-05-17
TW201620913A (zh) 2016-06-16
EP3130592A4 (en) 2017-09-06
CN106459057A (zh) 2017-02-22
ES2754590T3 (es) 2020-04-20
US20170029430A1 (en) 2017-02-02
KR101921486B1 (ko) 2018-11-26
ZA201607736B (en) 2017-09-27
CA2944801C (en) 2019-02-12
AU2015245786A1 (en) 2016-11-03
AU2015245786B2 (en) 2018-03-15
KR20170005807A (ko) 2017-01-16
RU2672722C2 (ru) 2018-11-19
RU2016144202A3 (en:Method) 2018-05-15
BR112016023397A2 (en:Method) 2017-08-15
DK3130592T3 (da) 2019-11-04
EP3130592A1 (en) 2017-02-15
US9856262B2 (en) 2018-01-02
MX2016013265A (es) 2017-05-03
SG11201608438YA (en) 2016-11-29
MX368496B (es) 2019-10-04
RU2016144202A (ru) 2018-05-15
PL3130592T3 (pl) 2020-05-18
JP2017510653A (ja) 2017-04-13
TWI671301B (zh) 2019-09-11
WO2015154630A1 (zh) 2015-10-15
JP6359175B2 (ja) 2018-07-18
CN106459057B (zh) 2019-06-07
HUE047410T2 (hu) 2020-04-28
PT3130592T (pt) 2019-11-21
EP3130592B1 (en) 2019-08-14
CA2944801A1 (en) 2015-10-15

Similar Documents

Publication Publication Date Title
ZA201607736B (en) Analogs of 4h-pyrazolo[1,5-a]benzimidazole compounds as parp inhibitors
IL287517A (en) Benzimidazole compounds as c-kit inhibitors
ZA201904568B (en) Benzodiazepine derivatives as rsv inhibitors
ZA201801032B (en) Bicyclic compounds as atx inhibitors
SMT202200250T1 (it) Composti eterociclici come inibitori della pi3k-gamma
IL254318B (en) History of benzaimidazoles as bromodomain inhibitors
IL255570A (en) Bicyclic compounds as atx inhibitors
ZA201701644B (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
IL251778B (en) Novel pyrazolopyrimidine histories as nik inhibitors
ZA201608442B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
IL256226A (en) Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
SG11201610770PA (en) Quinolizinone derivatives as pi3k inhibitors
ZA201700518B (en) Use of active compound compositions
PL3978500T3 (pl) Sposób wytwarzania tricyklicznych związków inhibitorów pi3k
IL266121A (en) A history of metamorphosed quinoxaline as an inhibitor of pfkfb

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed